Medications that are not allowed to be used with dabigatran etexilate (Pradaxa)

Dabigatran etexilate capsule (Pradaxa) is a direct thrombin inhibitor used for anticoagulation therapy. It is mainly used for stroke prevention in patients with non-valvular atrial fibrillation and the treatment of deep vein thrombosis and pulmonary embolism. During the use of dabigatran etexilate capsules, patients need to be careful to avoid interactions with some medications to prevent increased risks of bleeding or other adverse reactions. The following are some drugs that are contraindicated for use with dabigatran etexilate capsules:

1.Anticoagulant drugs: Simultaneous use with other oral anticoagulant drugs such as warfarin (warfarin) may increase the risk of bleeding. Because these drugs have similar mechanisms of action, using them together may cause excessive anticoagulation of the blood.

2. Antiplatelet drugs: Simultaneous use with antiplatelet drugs such as aspirin, clopidogrel, etc. may increase the risk of bleeding. These drugs also have the effect of inhibiting platelet aggregation, which is additive to the anticoagulant effect of dabigatran etexilate capsules.

3.Nonsteroidal anti-inflammatory drugs (NSAIDs): NSAIDssuch as ibuprofen, paracetamol, etc. may increase the risk of gastrointestinal bleeding. Caution is required when using dabigatran etexilate capsules at the same time. These drugs may affect platelet aggregation and coagulation.

4. Antifungal drugs: Potent antifungal drugs, such as fluconazole, may increase the plasma concentration of dabigatran etexilate capsules and increase the risk of bleeding.

5. PowerfulPglycoprotein inhibitors: Some powerful Pglycoprotein inhibitors, such as aminoglycoside antibiotics, may affect the metabolism of dabigatran etexilate capsules and increase their concentration in the body.

6. Benazepril: Benazepril is a commonly used high blood pressure drug, and its simultaneous use with dabigatran etexilate capsules may increase the risk of bleeding. Patients should be monitored by their doctor while using these two drugs.

7. Anti-epileptic drugs: Some anti-epileptic drugs, such as carbamazepine, may affect the metabolism of dabigatran etexilate capsules and increase the risk of bleeding.

8. Other coagulation inhibitors: Simultaneous use with other coagulation inhibitors, such as heparin, low molecular weight heparin, etc. may increase the anticoagulant effect and increase the risk of bleeding.

The above listed are some drugs that are prohibited from being combined with dabigatran etexilate capsules. However, in actual application, doctors will comprehensively consider the patient's specific situation and medication history, and may adjust the dosage or select other appropriate drugs. Before using dabigatran etexilate, patients should inform their doctor about all medications they are taking, including prescription drugs, over-the-counter drugs, and supplements. Doctors will evaluate potential interaction risks and develop an appropriate treatment plan based on the patient's overall health and medication history. Patients should pay close attention to any unusual bleeding or other symptoms of discomfort during medication and report them to their doctor in a timely manner.

Dabigatran etexilate capsules have been launched in China and have been included in medical insurance. Patients can purchase them domestically. Please consult the local hospital pharmacy for specific prices. The main foreign drug is the original drug of dabigatran etexilate capsules. The cheaper one is the Turkish version of the original drug from Germany. The price of 110mg*60 capsules is about three to four hundred, and the ingredients and efficacy are consistent with the original drug on the domestic market.